It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

A civic hospital employee from Mumbai passed away due to complications from Guillain-Barré Syndrome (GBS) after being hospitalized for nearly three weeks. The patient had visited Pune ...

Guillain-Barré Syndrome (GBS) is an uncommon but deadly disorder in which the immune system attacks the nerves, causing muscular weakness and sometimes paralysis. Recently, the National Institute ...

Eli Lilly (LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce ...

Eli Lilly plans four new U.S. manufacturing sites, expanding domestic production and reshoring pharmaceutical ingredient manufacturing. $50B expansion since 2020 includes four sites, creating over ...

GBS typically presented as slowly progressive weakness in the legs or arms. (Image Credits: Pixabay) GBS Outbreak: After a 59-year-old resident of Khadakwasla died due to Guillain-Barre Syndrome ...

GBS outbreak: The death count from the recent Guillain-Barre Syndrome (GBS) outbreak has risen to 11 after two more patients died in Pune hospitals during treatment, officials said on Wednesday ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...